CompletedNot Applicable

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Japan113 participantsStarted 2018-11-01

Plain-language summary

The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) in routine clinical practice.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Untreated participants
✓. CD30-positive participants
✓. Participants on concomitant Brentuximab vedotin and AVD

What they're measuring

Percentage of Participants With Grade 3 or Higher Neutropenia and Febrile Neutropenia

Timeframe: Up to 2 weeks after the last dose (approximately 6 months)

Trial details

NCT IDNCT03729609

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-09-27

Results submitted2024-03-26

View on ClinicalTrials.gov More Untreated CD30-Positive Hodgkin's Lymphoma trials